Management of acute myeloid leukemia (AML) is complex due to its various subentities. Nearly 6-7% of the patients with AML have somatic mutations in the isocitrate dehydrogenase 1 (IDH1) enzyme. This article summarizes a phase 3 study comparing the clinical efficacy of azacitidine in combination with ivosidenib (an IDH1 inhibitor) with that of azacitidine alone, in the treatment of newly diagnosed cases of AML with an IDH1 mutation.
Rationale The present further evaluated the findings of a previous phase 1b study that had reported an agreeable safety profile and a considerable clinical efficacy of ivosidenib and azacytidine combination in treating recently diagnosed AML patients with an IDH1 mutation. Study Details Results Key takeaways A combination of ivosidenib and azacytidine has an acceptable safety profile. It is clinically more effective than azacytidine alone in managing acute…
